Market Overview:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in adults worldwide, accounting for around 30% of newly diagnosed cases. It is an aggressive (fast-growing) type of blood cancer. It responds well to initial chemotherapy in many people but relapse is common.
Market key trends:
Relapsed or refractory DLBCL remains a significant unmet medical need. Most patients are unable to achieve durable remission with existing standard-of-care treatments. There is an increased focus on developing targeted therapies and immunotherapies for the treatment of relapsed or refractory DLBCL. CAR T-cell therapies such as axicabtagene ciloleucel and tisagenlecleucel have demonstrated high response rates and obtained regulatory approvals in the treatment of relapsed or refractory DLBCL. Biologic drugs targeting CD19, CD20 and PD-1/PD-L1 pathways are also being evaluated in clinical trials for this indication.
Segment Analysis
The global relapsed or refractory diffuse large B cell lymphoma market is segmented based on type, treatment, end-user, and region. The type segment is further divided into follicular lymphoma and diffuse large B cell lymphoma. Among these, diffuse large B cell lymphoma dominates the market with over 60% share owing to its high prevalence globally.
Key Takeaways
The global Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market is expected to witness high growth, exhibiting a CAGR of 4.3% over the forecast period, due to increasing investment in research and development by key players.
The market size is expected to reach US$ 1,479.5 Mn in 2023.
Regional analysis: North America dominates the market with over 40% share due to growing awareness regarding relapsed or refractory diffuse large B cell lymphoma and easy accessibility to advanced treatments in the region. Asia Pacific is expected to register fastest growth over the forecast period attributed to rising healthcare expenditures.
Key players: Key players operating in the relapsed or refractory diffuse large B cell lymphoma market are MorphoSys U.S. Inc., Bristol-Myers Squibb Company, Karyopharm Therapeutics, Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
